CVS Group Reports Strong Q4 Performance and Outlines Growth Strategy
CVS Group reported full-year revenue exceeding GBP 710 million, a 5.9% increase compared to the previous year. The company expects adjusted EBITDA in line with market consensus, maintaining margins around 20%. Net debt stood at approximately GBP 200 million, resulting in leverage of 1.63 times, well below its two-times limit. Australia is highlighted as a key growth area for CVS Group, where the company now operates 57 practice sites and has completed six acquisitions this year with more deals ongoing. Management anticipates that Australia could eventually contribute GBP 105 million to GBP 135 million in EBITDA annually. The firm reaffirmed its capital allocation strategy focused on maintaining a strong balance sheet, funding growth investments, returning cash through dividends, and executing a GBP 50 million buyback. CEO Richard Fairman noted that the veterinary market remains resilient due to long-term structural trends such as pet humanization and increased life expectancy. The company also mentioned challenges in Q4 from weak U.K. consumer confidence and extreme weather affecting customer behavior.
Topics: acquisitions capital_allocation ebitda_forecast revenue_growth